Diarrhea associated with weight loss injections likely results from multiple factors, though the precise mechanisms are not fully understood
Diarrhea is one of the most frequently reported side effects of semaglutide, a GLP-1 receptor agonist used to treat type 2 diabetes and support chronic weight management
Sustained release is achieved by incorporating exendin-4 into 0.06 mm diameter biodegradable microspheres containing 50:50 poly (D,L-lactide-co-glycolide) (PLG) polymer and sucrose
Leading players Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca, and Sanofi remain at the forefront of this transformation
A simple, consistent routine designed to support your wellness goals without complicated schedules or unnecessary additives.*
At its highest dose, 36 mg, participants in a phase 3 trial lost an average of 12.4 percent of their starting weight over 72 weeks